Abbott Laboratories (ABT) Q3 2026 Earnings Call Highlights: Accelerating Growth, Nutrition Spin-Off Plans, and Revised Guidance

gurufocus.com · 2026-10-21

Total Sales: Grew 7% on a comparable basis in Q3 2026, an acceleration versus the first half of the year.Adjusted EPS: $1.42, in line with guidance and consensu

TickrTrends take: Abbott Laboratories reported accelerating growth in Q3 2026 while announcing plans to spin off its nutrition business and revising guidance upward, developments that align with TickrTrends' current undervalued assessment of the company. The nutrition spin-off could unlock value by allowing investors to separately evaluate two distinct business models within the Healthcare sector, potentially addressing prior valuation constraints from the conglomerate structure. Valuation-focused investors should monitor how the market reprices ABT shares following the separation and whether the revised guidance translates into sustained earnings growth that justifies a higher multiple.

Read the full story at gurufocus.com →